Imagine for a moment that a virus started affecting about 5% of all pregnant women — 200,000 U.S. pregnancies per year. Imagine that it caused significant pregnancy complications above and beyond the baseline rate. More than 10% of those infected with the virus would miscarry; up to 20% or more would have preterm birth, and 30% of newborns would show effects of the exposure in the days after birth — sometimes severe, with seizures and trouble breathing. If this were to occur it would be considered a public health emergency and a tremendous effort would be put forth to address it. Yet this epidemic is happening and, in many ways, it is going unrecognized. Pregnant women and the public are unaware. It is the epidemic of antidepressant drug exposure during pregnancy.
Two articles came out last week showing that antidepressant use by pregnant women is associated with preterm birth. One of them also showed increased rates of neonatal seizures in newborns who were exposed to antidepressants in utero.
These articles join a large and growing body of literature that clearly demonstrates risks when pregnant women use antidepressants. These risks are all the more concerning given that there is no evidence of improvement of pregnancy outcomes with the use of antidepressants by pregnant women. There is an important question to ask: Are we exposing millions of pregnant women and their babies to a class of drugs that are causing significantly more harm than good?
Current research suggests that antidepressant use (typically the SSRIs) by pregnant women is associated with increased risks of miscarriage , birth defects, preterm birth, preterm premature rupture of membranes, preeclampsia, and decreased fetal growth.
After birth, newborns who were exposed to antidepressants in utero have increased rates of what is called the newborn behavioral syndrome which can consist of a variety of symptoms including tremors, agitation, excessive crying, respiratory difficulties, and seizures. Exposed newborns also have been shown to have changes in heart conduction (i.e, the prolonged QT syndrome) and a potentially fatal condition called Persistent Pulmonary Hypertension of the Newborn (PPHN) in which the arteries to the baby’s lungs are constricted leading to trouble breathing or, in severe cases, death.
Many of these risks are not rare. Rates of miscarriage in women taking antidepressants are estimated at greater than 10%. In some studies rates of preterm birth in the antidepressant exposed groups have been greater than 20%. Ten percent of babies exposed to SSRIs in utero will show the prolonged QT syndrome on their EKG . And up to 30% of exposed babies will develop the newborn behavioral syndrome.
Long Term Effects?
What is particularly concerning in this area is the issue of possible long term effects on the developing brains of exposed babies. Developing embryos and fetuses are loaded with serotonin receptors and the serotonergic system plays a crucial role in fetal development. What happens to human development of the brain and behavior when we alter this system? We simply have no idea and we are currently witnessing what amounts to a large uncontrolled experiment on human development.
The current research data is not reassuring. Animal data clearly shows that fetal exposure to antidepressants can lead to changes in the development of the brain and changes in behavior. Studies are available that demonstrate effects on the branching of neurons--the basic cell in the nervous system . Human studies have shown that children who were exposed to antidepressant in utero have changes in motor development and behavior. Last July (2011) researchers at Kaiser in California showed a doubling of the risk of autism with prenatal exposure to antidepressants. And this doesn’t appear to be a “chance” finding. For decades serotonin has been implicated in the etiology of autism .
Pregnant And Depressed
Many of these risks might be tolerable if there was evidence of pregnancy benefit with the use of antidepressants by pregnant women. “After all,” you might think, “cancer drugs have risks too but we use them because they cure cancer.” But, sadly, there is no evidence of obstetrical benefit with the use of these drugs by pregnant women. In study after study the group of women on the antidepressants have worse pregnancy outcomes, not better. For example, they have more miscarriages, more preterm birth, and more neonatal complications.
For years, the key opinion leaders in this area (most of whom are paid sizeable amounts by the drug industry) have been pitching the idea that pregnant women, by taking antidepressants, will improve their mood and that this will lead to better pregnancy outcomes. The conventional wisdom has been that depression is like diabetes and depressed pregnant women need to stay on their antidepressants just like pregnant diabetics need to take their insulin. And this counseling gets repeated on a daily basis in doctors’ offices around the globe and in news reports on this topic. The problem is that it just isn’t true: pregnancy outcomes do get better when diabetics take their insulin but this isn’t true with antidepressants. We had all hoped that the pregnancies of depressed women could be helped with drugs, but the scientific literature does not support the idea that antidepressant use in pregnancy improves outcomes. In fact, it’s just the opposite. When you take a group of depressed pregnant women and compare them to depressed pregnant women taking antidepressants, it’s the group that is taking the antidepressants that has the increased rates of pregnancy complications.
What's A Woman To Do?
So what should we tell pregnant women and women of childbearing age who are taking these drugs? As a Maternal-Fetal Medicine consultant, I deal with this issue regularly. And for me the key is transparency and properly informing the patients and the public. Who can argue with giving pregnant women full information about a drug they are taking? And the truth is that full information in this area means telling women that antidepressant use during pregnancy has been associated, in study after study, with pregnancy complications and no evidence of better pregnancy results.
I frequently give lectures on this topic and am asked “What about the woman with severe depression who is suicidal when she comes off her antidepressant?” To me, it sounds like she should stay on the medication. But, let’s be clear, the vast majority of women on these drugs have mild to moderate depression. Furthermore, my main point on this is not that we should be telling anyone what to do. Psychotropic medication use during pregnancy is a personal choice and these women need care and support. But what they also need is accurate, correct, and complete information so they can make an informed decision; that is not what is currently happening.
We are currently seeing what amounts to an epidemic of antidepressant drug exposure during pregnancy and there is a pervasive lack of public information and understanding on this topic. Pregnant women need accurate information about drugs they take. I am surprised on a regular basis by my colleagues in obstetrics and psychiatry who are simply unaware of the large body of scientific studies clearly showing antidepressants to be associated with pregnancy complications. What pregnant patients choose to do with this information is up to them, but patients and the broader public deserve to be told the truth about the risks of antidepressant use during pregnancy.
Adam C. Urato, MD is a maternal-fetal medicine physician at Tufts Medical Center, Assistant Professor of Obstetrics & Gynecology at Tufts University School of Medicine and Chairman, Department of Obstetrics & Gynecology, MetroWest Medical Center in Framingham
This program aired on June 12, 2012. The audio for this program is not available.